T cell receptor reversed polarity recognition of a self-antigen major histocompatibility complex by Beringer, Dennis X. et al.
Oncotarget24649www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 6, No. 28
Eliminating roles for T-bet and IL-2 but revealing superior 
activation and proliferation as mechanisms underpinning 
dominance of regulatory T cells in tumors
Emily J. Colbeck1,*, James P. Hindley1,*, Kathryn Smart1, Emma Jones1, Anja 
Bloom1, Hayley Bridgeman1, Rhoanne C. McPherson2, Darryl G. Turner2, Kristin 
Ladell1, David A. Price1, Richard A. O’Connor2, Stephen M. Anderton2, Andrew J. 
Godkin1 and Awen M. Gallimore1
1 Institute of Infection Immunity and Biochemistry, Cardiff University School of Medicine, Cardiff, UK
2 MRC Centre for Inflammation Research, Centre for Multiple Sclerosis Research and Centre for Immunity Infection and 
Evolution, University of Edinburgh, Edinburgh, UK
* These authors have Contributed equally to this work
Correspondence to: Awen M. Gallimore, email: GallimoreAM@cardiff.ac.uk
Keywords: Treg, cancer, proliferation, T-bet, CD69, Immunology Section, Immunity, Immune response
Received: July 18, 2015 Accepted: August 22, 2015 Published: September 10, 2015
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original author and source are credited. 
AbstrAct
Foxp3+ regulatory T cells (Tregs) are often highly enriched within the tumor-
infiltrating T cell pool. Using a well-characterised model of carcinogen-induced 
fibrosarcomas we show that the enriched tumor-infiltrating Treg population comprises 
largely of CXCR3+ T-bet+ ‘TH1-like’ Tregs which are thymus-derived Helios+ cells. 
Whilst IL-2 maintains homeostatic ratios of Tregs in lymphoid organs, we found that 
the perturbation in Treg frequencies in tumors is IL-2 independent. Moreover, we 
show that the TH1 phenotype of tumor-infiltrating Tregs is dispensable for their ability 
to influence tumor progression. We did however find that unlike Tconvs, the majority 
of intra-tumoral Tregs express the activation markers CD69, CD25, ICOS, CD103 and 
CTLA4 and are significantly more proliferative than Tconvs. Moreover, we have found 
that CD69+ Tregs are more suppressive than their CD69- counterparts. Collectively, 
these data indicate superior activation of Tregs in the tumor microenvironment, 
promoting their suppressive ability and selective proliferation at this site. 
IntroductIon
CD4+ Foxp3+ regulatory T cells (Tregs) serve to 
maintain immune homeostasis, prevent autoimmunity 
and limit immunopathology [1]. It is also well known 
from studies of mouse models and cancer patients, that 
Tregs are enriched in tumors where they often facilitate 
disease progression [2-5]. We have used a mouse model 
of chemical carcinogenesis whereby fibrosarcomas are 
induced in vivo following administration of the chemical 
carcinogen, 3-methylcholanthrene (MCA) to identify 
factors promoting enrichment of intra-tumoral Tregs. 
This model is useful and relevant as there is a highly 
significant enrichment of Tregs within the fibrosarcomas, 
and depletion of these Tregs results in T cell mediated 
control of tumor progression [4, 6, 7]. 
Interleukin-2 (IL-2), secreted primarily by CD4+ 
Foxp3- T cells, plays a crucial role in maintaining immune 
tolerance. Tregs do not produce IL-2 but constitutively 
express CD25 (part of the high affinity IL-2 receptor), 
suggesting they may have the ability to compete for the 
IL-2 resource provided by other T cells. Indeed, under 
homeostatic conditions, the frequency of Tregs in the 
periphery is regulated by the number of IL-2 producing 
T cells [8, 9]. The tightly controlled ratio of Tconv to 
Treg under normal conditions is significantly perturbed 
in the microenvironment of tumors in mice and humans, 
where Tregs can represent up to 40-50% of the CD4+ T 
cell pool [4, 5]. It is possible therefore that IL-2 is limited 
in the tumor microenvironment and that the perturbation 
in Tconv to Treg ratios reflects competition for limited 
IL-2 at this site. There is also a growing consensus that 
Tregs differentiate into distinct lineages optimised in their 
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ability to suppress specific Tconv subsets [10-13]. Thus, 
the demonstration that T-bet+ CXCR3-expressing Tregs 
accumulate in human ovarian cancer has lent support to 
the theory that Tregs must ‘mirror’ the TH1-orientated anti-
tumor response in order to effect immunosuppression [14].
In the study described herein we investigate 
whether expression of T-bet and / or competition for 
IL-2 is important for Treg-mediated suppression of 
tumor immunity. We also explore potential drivers 
of Treg accumulation in tumors, identifying superior 
activation and proliferation of intra-tumoral Tregs as key 
factors underpinning their ability to dominate this highly 
immunosuppressed site.
results
Intra-tumoral Foxp3+ tregs proliferate more than 
Foxp3- tconvs
Tregs are highly enriched within the 
microenvironment of MCA-induced tumors, reaching 
40-50% of the CD4+ T cell pool [4, 7, 15]. To determine 
why this should be the case, we initially measured the 
proliferative status of Tconv and Treg within tumor-
bearing mice by Ki67 expression. Ki67 is a nuclear protein 
expressed during all active phases of the cell cycle and 
hence is used as a marker of cellular proliferation [16]. A 
higher proportion of Tregs expressed Ki67 compared to 
Tconv cells within all of the sites (spleen, lymph nodes 
and tumor), in both tumor-bearing and naïve mice (Figure 
1A-1B). Notably, by far the most significant difference 
between the proportions of proliferating Tconv and Treg 
cells was observed within the tumor (Figure 1C). 
Highly proliferative tumor-infiltrating Foxp3+ 
tregs are thymus-derived Helios+ t cells 
TCR clonotypes are largely distinct between 
Foxp3- and Foxp3+ CD4+ tumor-infiltrating T cell sub-
populations, indicating that conversion does not account 
for intra-tumoral Treg-enrichment and supporting the 
hypothesis that Tregs within the tumor are thymus-derived 
Tregs (tTregs) [17]. The Ikaros transcription factor family 
member, Helios, is expressed predominantly in tTregs 
[18]. As shown in Figure 1D and 1E, Helios staining was 
observed mainly in the Foxp3+ population, and indeed, the 
vast majority of proliferating Foxp3+ cells also express 
Helios. These data confirm that the highly proliferative 
Tregs in the tumor are thymus-derived Helios expressing 
Tregs. 
In order to assess the activation status of intra-
tumoral Tregs, flow cytometric analysis of the expression 
of a number of markers associated with T cell activation 
were examined on both intra-tumoral Tregs and Tconvs 
(CD25, CD44, CD103, CTLA4, ICOS). Tregs within the 
tumor demonstrated significantly higher expression levels 
of all activation markers studied than Tconvs (Figure 1F). 
These data confirm that Foxp3+ tTregs within the tumor are 
not only significantly more proliferative but also exhibit a 
more activated phenotype than Tconvs at this site.
Tumor-infiltrating Tconvs and Tregs are enriched 
for inflammation-seeking “TH1-like” cells
TH1 and cytotoxic T lymphocyte (CTL) responses 
limit progression of MCA-induced fibrosarcomas after 
Treg depletion [4, 7, 19, 20]. Previous studies have 
reported that Tregs can express the chemokine receptor 
CXCR3 in response to TH1 polarising cues, and that 
these CXCR3+ Tregs accumulate at peripheral sites 
of inflammation to specifically suppress TH1 and CTL 
responses [10, 11, 14, 21]. When we analysed tumor-
infiltrating T cells for CXCR3 expression, a high 
proportion (approximately 60%) of tumor-infiltrating 
Tregs were CXCR3+ (Figure 2A-2B). Furthermore, the 
majority of Ki67+ proliferating Tregs in the tumor co-
expressed CXCR3, as was true for intra-tumoral Tconvs 
(Figure 2A-2C). We also found T-bet expression in a 
proportion of both intra-tumoral Tconv and Treg cells 
(Figure 2D-2E). 
It was hypothesised that if, as suggested in the 
literature [10, 11], T-bet expression is necessary for the 
ability of Tregs to suppress TH1 responses and promote 
tumor growth, then tumor development should be better 
controlled in the absence of T-bet expressing Tregs. We 
used mice genetically engineered to lack T-bet expression 
in Foxp3+ cells (T-betfl/flFoxp3-Cre conditional KO mice) 
[22]. As CXCR3 expression is under the control of T-bet 
in Treg cells, Treg in T-betfl/flFoxp3-Cre conditional KO 
mice also display abolished CXCR3 expression [11, 22]. 
We confirmed the lack of CXCR3 expression in Foxp3+ 
Tregs at the protein level by flow cytometric analysis of 
blood (Figure 2F). To test the hypothesis, we compared the 
incidence of MCA-induced tumors in T-betfl/flFoxp3-Cre 
conditional KO and WT C57BL/6 mice and found tumor 
incidence was comparable between the groups (Figure 
2G). Thus, whilst these data show that in MCA-induced 
tumors, approximately 50% of tTregs are “TH1-like”, we 
have no evidence that T-bet is required for Treg-mediated 
suppression in the tumor environment. Moreover, 
proportions of intra-tumoral Tregs were comparable in 
T-betfl/flFoxp3-Cre conditional KO and WT mice (data not 
shown).
competition for Il-2 does not account for the 
enrichment of intra-tumoral Foxp3+ tregs
We postulated that competition for IL-2 represents 
a key component of intra-tumoral Treg proliferation and 
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Figure 1: Tumor infiltrating Foxp3+ cd4+ tregs are more proliferative and activated than conventional Foxp3- cd4+ 
t cells, and are thymus-derived Helios+ tregs. Single cell suspensions prepared from spleen, lymph nodes and tumor of naïve or 
tumor-bearing mice were stained using CD4-, Foxp3-, Ki67- and Helios- specific monoclonal antibodies and analysed by flow cytometry. 
1A. Representative flow cytometry plots from one animal showing proportion of Ki67+ proliferating Tconvs and Tregs, once gated on CD4+ 
Foxp3- cells (left panels) or CD4+ Foxp3+ cells (right panels), in tumor draining lymph node (DLN), and tumor. 1b. Proportion of CD4+ 
Foxp3- Tconvs (white bars) and CD4+ Foxp3+ Tregs (grey bars) expressing Ki67 in spleen, lymph node (LN), tumor non draining lymph 
node (NDLN), DLN, and tumor. N = 6 naïve; N = 5 tumor-bearing mice. Data are represented as mean ± SEM. Statistical significance was 
determined by individual paired t-tests between Tconvs and Tregs in each compartment, and Tregs in tumor and spleen, and NDLN and 
DLN, of tumor-bearing animals. The most highly significant difference was found between Tconvs and Tregs within tumors. 1c. A dot plot 
showing the differential (% of Ki67+ Foxp3+ Tregs minus % of Ki67+ Foxp3- Tconv) Ki67 expression in spleen, NDLN, DLN and tumor. 
N = 5. Data are represented as individual data points plus mean. Statistical significance was determined by individual paired t-tests. 1d. 
Representative flow cytometry plots from one animal showing proportion of Ki67+ proliferating Tconvs and Tregs expressing Helios, gated 
on CD4+ Foxp3- cells (left panels) or CD4+ Foxp3+ cells (right panels), in DLN, and tumor. Numbers represent the proportion of either Ki67+ 
Tconv (left panels) or Ki67+ Treg (right panels) that also express the marker Helios, gated on CD4+ Foxp3- Ki67+ cells (left panels) or CD4+ 
Foxp3+ Ki67+ cells (right panels). 1e. A dot plot showing that the vast majority of CD4+ Foxp3+ Ki67+ Tregs also express Helios in spleen, 
LN, NDLN, tumor draining lymph node (DLN), and tumor. N = 5. Data are represented as individual data points plus mean. Statistical 
significance was determined by individual paired t-tests. 1F. Proportion of CD4+ Foxp3- Tconvs (white bars) and CD4+ Foxp3+ Tregs (grey 
bars) expressing various activation markers in the tumor. N = 10 for CD25, 9 for CD44, 13 for CD103, 8 for CTLA-4, 12 for ICOS. Data 
are represented as mean ± SEM. Statistical significance was determined by individual paired t-tests. 
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Figure 2: Tumor-infiltrating Tconvs and Tregs are enriched for inflammation-seeking “TH1-like” cells. Single cell 
suspensions prepared from spleen, NDLN, DLN and tumor were stained using CD4-, Foxp3-, Ki67-, CXCR3- and T-bet- specific 
monoclonal antibodies and analysed by flow cytometry. 2A. Representative flow cytometry plots from one animal showing proportion of 
Ki67+ proliferating Tconvs and Tregs that also express the chemokine receptor CXCR3, once gated on CD4+ Foxp3- cells (left panels) or 
CD4+ Foxp3+ cells (right panels), in tumor. 2b.-2c. Proportion of CD4+ Foxp3- Tconvs (white bars) and CD4+ Foxp3+ Tregs (grey bars) (B), 
and those expressing Ki67 (C), that also express CXCR3 in spleen, NDLN, DLN, and tumor. N = 5. Data are represented as mean ± SEM. 
Statistical significance was determined by individual paired t-tests. 2d. Representative flow cytometry plots from one animal showing 
proportion of T cells that express the transcription factor T-bet, once gated on CD4+ Foxp3- Tconvs (left panels) or CD4+ Foxp3+ Tregs 
(right panels), in tumor (pale grey peak, solid outline), relative to the isotype matched control sample (dark grey peak, dashed outline). 2e. 
Proportion of CD4+ Foxp3- Tconvs (white bars) and CD4+ Foxp3+ Tregs (grey bars) expressing T-bet in spleen, NDLN, DLN, and tumor. 
N = 5. Data are represented as mean ± SEM. Statistical significance was determined by individual paired t-tests and Tregs in tumor and 
spleen. 2F. A representative flow cytometry plot from blood samples of one Wild Type C57BL/6 mouse (dark grey peak, solid outline) and 
one T-betfl/flFoxp3-Cre conditional KO mouse (pale grey peak, solid outline), showing the proportion of Foxp3+ Tregs that express CXCR3. 
Cells are gated on live CD4+ Foxp3+ lymphocytes. The number represents the proportion of cells that express CXCR3 in Wild Type 
C57BL/6 blood. 2G. Incidence of MCA-induced tumors, as measured by percent of animals tumor free X days after MCA injection. Solid 
line represents Wild Type C57BL/6 mice; dashed line represents T-betfl/flFoxp3-Cre conditional KO mice. N = 4. Statistical significance was 
determined by a log rank (Mantel-Cox) test.
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subsequent enrichment. In line with this hypothesis, we 
found that a lower proportion of intra-tumoral Tconv 
expressed intra-cellular IL-2 compared to secondary 
lymphoid organs (Figure 3A). To determine whether 
provision of IL-2 would restore homeostatic ratios of 
Tregs and Tconvs in the tumor, we injected tumor-bearing 
mice with anti-IL-2/IL-2 complexes (S4B6-1-IL-2 which 
binds CD122, stimulating both Tregs and Tconvs) [23] 
which resulted in a significant increase in proliferation of 
Tregs and Tconvs in lymphoid tissues but not the tumor 
(Figure 3B). Accessibility of the S4B6-1-IL-2 complex 
to the tumor mass was not an issue as the proportion of 
Ki67+ proliferating CD8+ T cells in the tumor significantly 
increased following complex administration (mean of 
26.8% for non-treated versus mean of 74.6% for S4B6-
1-IL-2 treated; ***P = 0.0010 by paired t test; data not 
shown). Furthermore, whereas administration of this anti-
IL-2/IL-2 complex altered the ratio of Tconvs to Tregs in 
Figure 3: competition for Il-2 does not account for the enrichment of intra-tumoral Foxp3+ tregs. Single cell suspensions 
prepared from spleen, NDLN, DLN and tumor from PBS-treated or anti-IL-2/IL-2 complex (S4B6-1) treated animals, were stained 
using CD4-, Foxp3-, CD8-, Ki67- and IL-2- specific monoclonal antibodies and analysed by flow cytometry. 3A. A dot plot showing the 
proportion of CD4+ Foxp3- Tconvs expressing intra-cellular IL-2 in spleen, NDLN, DLN, and tumor of non-treated animals. N = 8. Data 
are represented as individual data points plus mean. Statistical significance was determined by individual paired t-tests. 3b. Proportion of 
CD4+ Foxp3- Tconvs (white bars) and CD4+ Foxp3+ Tregs (grey bars) expressing Ki67 in spleen, NDLN, DLN, and tumor, of PBS-treated 
or anti-IL-2/IL-2 complex (S4B6-1) treated animals. Data are represented as mean ± SEM. Statistical significance was determined by 
individual paired t-tests. 3c. Ratio of CD4+ Foxp3- Tconvs to CD4+ Foxp3+ Tregs in spleen, NDLN, DLN, and tumor, in animals treated 
with anti-IL-2/IL-2 complexes (S4B6-1; open shapes) or control animals treated with phosphate buffered saline (PBS; closed shapes). Data 
are represented as individual data points plus mean. Statistical significance was determined by individual paired t-tests.
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favour of Tregs in secondary lymphoid tissues, the ratio 
of Tconvs to Tregs in the tumor did not change (Figure 
3C). These data indicate that IL-2 is not a limiting factor 
for proliferation of Tregs or Tconvs in the tumor and that 
increasing the availability of IL-2 has no impact on the 
ratio of Tregs to Tconvs at this site.
cd69 is highly expressed on intra-tumoral Foxp3+ 
tregs and denotes tregs with superior suppressive 
capacity
The data presented thus far indicate that the more 
activated phenotype of intra-tumoral Tregs is linked to 
superior proliferation and hence their enrichment within 
the tumor-infiltrating T cell pool. To further address the 
implications of superior Treg activation within the tumor 
microenvironment we turned our attention to the early 
activation marker, CD69 [24] as it has recently become 
apparent that CD69, through reciprocal regulation of 
sphingosine 1-phosphate receptor-1 (S1P1), retains CD69+ 
T cells at the site of antigen [25-27]. Moreover, CD69+ 
Foxp3+ Tregs are reportedly more efficient at limiting 
inflammation than their CD69- counterparts [28], implying 
that CD69 acts as a negative regulator of T cell activation. 
We compared CD69 expression on MCA-tumor-
derived Foxp3- and Foxp3+ CD4+ T cells and found a 
striking difference in that the proportion of Foxp3+ CD4+ 
T cells (mean of 35.4% ± 7.0 SEM) was at least double 
that of Foxp3- CD4+ cells (mean of 13.1% ± 3.0 SEM) 
(Figure 4A). The same pattern was observed when we 
compared CD69 expression on Tregs and Tconvs isolated 
from tumors of the 4T1 breast carcinoma model. These 
data corroborated our findings in the MCA tumor model, 
as again a significantly higher proportion of tumor 
derived Foxp3+ Tregs expressed CD69 (mean of 37.1% 
± 9.3 SEM) relative to tumor derived Foxp3- Tconv 
(mean of 13.9% ± 2.3 SEM) (Figure 4A). These highly 
significant differences in CD69 expression between Tregs 
and Tconvs within both types of tumor is most striking 
when analysed by Mean Fluorescence Intensity (MFI) 
measurement (Figure 4B-4C). The significant enrichment 
of CD69-expressing Tregs in both MCA and 4T1 tumor 
models is presented using pie charts displaying relative co-
expression of markers Helios, Ki67 and CD69 in Figure 
4D. 
 We next sought to compare the suppressive 
capacity of CD69+ and CD69- Tregs. CD4+ CD25lo Tconvs 
were sorted from lymphoid tissue and co-cultured in the 
presence of anti-CD3 and anti-CD28 beads with either 
CD69+ or CD69- Tregs sorted from tumor draining or 
non tumor draining lymph nodes, at varying Tconv : Treg 
ratios. Treg were sorted as CD4+ CD25hi CD127lo (CD69+ 
or CD69-) cells. After 120 hours of culture, proliferation 
of labelled Tconvs was measured by flow cytometry 
(Figure 4E). Strikingly, CD69+ Tregs, recovered from 
tumor draining and non-draining lymph nodes, were 
more suppressive of Tconv proliferation than their CD69- 
counterparts. We observed that CD69+ Tregs are 1.3 x 
and 2 x more suppressive than CD69- Tregs at a Tconv 
: Treg ratio of 8 : 1 in the NDLN and DLN, respectively. 
Similarly, CD69+ Tregs are 1.3 x and 1.2 x more 
suppressive than CD69- Tregs at a Tconv : Treg ratio of 4 : 
1 in the NDLN and DLN, respectively (Figure 4E). These 
data are indicative of a superior ability of CD69+ Foxp3+ 
Tregs to suppress proliferation of anti-tumor Tconv cells, 
in relation to CD69- Foxp3+ Tregs. 
dIscussIon
The observation that Tregs are enriched in tumors 
has been made using numerous mouse models and through 
the study of cancer patients [2-5]. The aim of this study 
was to investigate the mechanism of this enrichment, 
employing a carcinogen-induced tumor model to examine 
Treg phenotype with respect to their intra-tumoral 
accumulation and suppressive function. 
A side-by-side analysis of the proliferation and 
survival characteristics of intra-tumoral Tregs and 
Tconvs revealed significant differences between the 
two T cell populations. The proportion of Ki67+ Tregs 
was significantly higher than Tconvs in spleens and 
lymph nodes, corroborating previous observations [29]. 
However, the novel data presented herein indicate that 
the extent of this difference is most striking in T cells 
recovered from the tumor mass. Enhanced proliferation 
was not accompanied by greater cell death within the Treg 
population (data not shown) thus superior proliferation 
of Tregs must contribute to their enrichment within the 
tumor. Preferential proliferation and accumulation of Tregs 
in the tumors does not reflect increased competition for 
IL-2, as increasing the availability of IL-2 has no impact 
on the ratio of Tregs to Tconvs at this site. These findings 
also indicate that Tconvs are not held in check through 
competition for IL-2. Whilst increasing the availability 
of IL-2 had no impact on proliferation of intra-tumoral 
Tregs or Tconvs, a significant increase in proliferation 
of CD8+ T cells was observed. Whilst the reason for this 
disparity is unclear, it is possible that intratumoral CD4+ 
T cells (unlike CD8+ T cells at the same site) are highly 
differentiated, and hence no longer proliferate in response 
to IL-2. 
The proliferating Tregs in tumors expressed 
both CXCR3 and T-bet, in keeping with a “TH1-like” 
lineage, and Helios, a marker thought to define thymus-
derived Tregs. We have no evidence however that T-bet 
expression defines Tregs with a superior capacity to 
suppress anti-tumor immune responses, which in the case 
of the MCA-induced fibrosarcomas described herein is 
a TH1-orientated response [6, 19, 20]. These data are in 
contrast to the previous observations made by Koch and 
colleagues, where T-bet deficient Tregs were inferior to 
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wild-type Tregs during control of TH1-mediated multi-
organ autoimmunity [11]. However, several studies have 
reported either no alteration in suppressive capacity 
of Tregs when T-bet is absent [30, 31] or even superior 
suppressive function of T-bet deficient Tregs [32]. A recent 
study using experimental autoimmune encephalomyelitis 
(EAE) reported that lack of T-bet expression in Foxp3+ 
Tregs did not hinder their infiltration of the inflamed 
central nervous system, which is important for EAE 
resolution. T-bet deficient Tregs were also capable of 
preventing the development of T cell-driven colitis 
[22]. These data together with our own tumor-related 
data question the relevance of peripheral differentiation 
of Tregs as a means of steering their function towards 
selective inhibition of a particular type of immune 
response. It is possible that expression of T-bet, and indeed 
other master transcription factors, by Tregs could simply 
be a reflection of chronic exposure to pro-inflammatory, 
activating signals in certain disease settings, rather than a 
requirement for specific functionality. 
This study also examined a role for CD69, a C-type 
lectin, upregulated on T cells upon antigen stimulation 
[24]. Paradoxically, CD69-/- mice exhibit enhanced tumor 
immunity and enhanced susceptibility to autoimmune 
disease raising the possibility that the molecule is a 
negative regulator of T cell activation [33, 34]. It is 
possible that this effect of CD69 is mediated by Foxp3+ 
Tregs, as CD69+ Foxp3+ Tregs have been shown to limit 
inflammation more efficiently than CD69- Tregs [28]. 
This effect of CD69 may relate to reciprocal regulation 
of CD69 and S1P1 signalling [25-27]. As S1P1 signalling 
upregulates the Akt-mTOR pathway, resulting in 
diminished suppressor activity in Tregs [35], it follows 
that CD69+ Treg would exhibit increased suppressor 
activity. Our findings support this premise. It has also 
become apparent that CD69 plays a role in retaining T 
cells at the site of antigen, through preventing expression 
of S1P1, thereby stopping lymphocyte egress from the 
site of antigen recognition [25-27]. Thus, in the case of 
the tumors described herein, the consequence of CD69 
expression on Tregs may be the retention of tumor-
infiltrating super-suppressors thereby ensuring Treg 
dominance within the tumor microenvironment.
In conclusion, we have eliminated competition for a 
limited IL-2 resource as a means by which Tregs become 
significantly enriched in tumors. Despite the discovery 
of an accumulation of TH1-like Tregs in tumors, this 
feature did not contribute to the functional ability of Tregs 
to control anti-tumor immune responses. Instead, our 
observations highlight increased proliferation of highly 
suppressive CD69+ Tregs as a mechanism by which Tregs 
exert dominance within the tumor microenvironment. 
MAterIAls And MetHods
Mice
Mice expressing the primate diphtheria toxin 
receptor (DTR) under the control of the Foxp3 promoter 
(Foxp3DTR mice) were obtained from Professor Alexander 
Rudensky and have been described previously [36]. 
Foxp3DTR mice were backcrossed with C57BL/6 mice for 
10 generations and housed in accordance with UK Home 
Office regulations under specific pathogen free conditions. 
In this study, mice were not administered diphtheria toxin 
so had normal proportions of Foxp3+ lymphocytes. T-betfl/
flFoxp3-Cre conditional KO mice were gratefully received 
from Professor Stephen Anderton and have been described 
previously [22].
Figure 4: cd69 is highly expressed on intra-tumoral Foxp3+ tregs and denotes superior suppressive capacity. 4A.-4d. 
Single cell suspensions prepared from spleen, NDLN, DLN and tumor were stained using CD4-, Foxp3-, and CD69- specific monoclonal 
antibodies and analysed by flow cytometry. 4A. Representative flow cytometry plots from one animal per model showing proportion of 
CD4+ Foxp3- Tconvs and CD4+ Foxp3+ Tregs that express CD69, once gated on CD4+ Foxp3- (left panels) or CD4+ Foxp3+ (right panels), in 
tumor (pale grey peak, solid outline), relative to the isotype matched control sample (dark grey peak, dashed outline). A tumor of the MCA-
induced fibrosarcoma model is shown in the top panel; a tumor of the 4T1 breast carcinoma model is shown in the bottom panel. 4b.-c. 
Proportion of CD4+ Foxp3- Tconvs (white bars) and CD4+ Foxp3+ Tregs (grey bars) expressing CD69 in spleen, NDLN, DLN, and tumor, 
expressed as Mean Fluorescence Intensity (MFI), for the MCA-induced fibrosarcoma model (B) and the 4T1 breast carcinoma model 
(C). N = 3 (B), N = 8 (C). Data are represented as mean ± SEM. Statistical significance was determined by individual paired t-tests. 4d. 
Representative pie charts depicting relative co-expression of Foxp3, Helios, Ki67 and CD69 by CD4+ T cells in spleen and tumor samples 
from one animal of the MCA-induced fibrosarcoma model (top panel) and one animal of the 4T1 breast carcinoma model (bottom panel). 
Each arc represents one of the four individual markers, as shown in the key included in the figure. 4e. Sorted Tconv and Treg populations 
were co-cultured in an in vitro Treg suppressor assay after which populations were analysed for proliferation by flow cytometry. Histograms 
showing the proportion of divided Tconv cells according to dilution of CellTrace Violet dye (x axis) with no CD3/CD28 stimulation (filled 
in red peak), with stimulation (purple peak), with stimulation in the presence of CD69- Tregs (green peak), and with stimulation in the 
presence of CD69+ Tregs (blue peak). Ratios of Tconv : Treg are shown above each set of histograms. Numbers on histograms represent % 
divided cells, colour-coded for each condition. Data are shown for CD4+ CD25hi CD127lo CD69+ or CD69- Tregs isolated from (DLN, top) 
and (NDLN, bottom).
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tumor induction
For tumor induction, Foxp3DTR mice or T-betfl/
flFoxp3-Cre conditional KO mice, aged 8 to 15 weeks, 
were injected subcutaneously in the left hind leg with 
400μg of 3-methylcholanthrene (MCA; Sigma-Aldrich) 
in 100μl of olive oil under general anaesthetic, as 
previously described [17]. Mice were monitored for 
tumor development weekly for up to 2 months and daily 
thereafter. Tumor-bearing mice were culled when their 
tumors were between 1cm and 2cm in diameter, typically 
100-150 days after MCA injection. 
Administration of Anti-Il-2 / Il-2 complexes
For treatment with Anti-IL-2/IL-2 complexes, 
5μg rIL-2 (PeproTech) was incubated with 50μg of anti-
IL-2 mAb (S4B6-1; Bio-Xcell) for 10 minutes at room 
temperature, prior to injection. Following development 
of a palpable tumor, complexes were administered by 
intraperitoneal injection in 200μl of solution every day for 
three consecutive days before sacrifice. 
Preparation of single cell suspensions for antibody 
staining and flow cytometry
Single cell suspensions of spleen, and inguinal 
lymph nodes (LN) were prepared by homogenising tissues 
in multiwell plates using the back of a syringe plunger. 
The inguinal LN from the tumor (left) side of the mouse 
was taken as the tumor draining LN and the contralateral 
inguinal LN was considered to be a non-draining LN. 
Dissected tumors were initially diced into a pulp using 
a scalpel before homogenisation. Homogenised tissues 
were resuspended in complete RPMI (RPMI [Invitrogen] 
supplemented with 2mM L-glutamine, 1mM sodium 
pyruvate, 50μg/ml penicillin streptomycin and 10% foetal 
calf serum) and filtered through 70μM cell strainers (BD 
Biosciences). Single cell suspensions were centrifuged 
at approximately 450g for 5 minutes and cell pellets 
were resuspended in FACS buffer (phosphate buffered 
saline (PBS) containing 5mM EDTA and 2% foetal calf 
serum). Prior to staining, spleen and tumor cell pellets 
were subjected to red blood cell lysis by resuspending cell 
pellets in 5ml RBC Lysis buffer (1/10 dilution in dH2O; 
BioLegend) for 90 seconds at room temperature. 
cell surface staining
Single cell suspensions were plated in 96 round-
bottomed well plates at 0.5-1 million cells per well. Cells 
were washed twice in PBS prior to live/dead staining by 
adding 3μl (or 6μl for tumor cell pellets) of LIVE/DEAD 
Aqua (diluted 1:10 in PBS; Invitrogen) for 15 minutes in 
the dark at room temperature. Cells were washed twice in 
FACS buffer prior to Fc Receptor blocking by adding 5mg/
ml anti-CD16/32 (93; eBioscience) antibody to the cells 
and incubating for 10 minutes at 4°C in the dark. After 
two washes in FACS buffer, cells were stained with 25-
50μl of antibodies diluted in FACS buffer and incubated at 
4°C in the dark for 10-15 minutes. Cell surface antibodies 
consisted of anti-CD3-PECy5 (17A2; BD Biosciences), 
anti-CD4-APC-eFluor 780 (RM4-5; eBioscience), anti-
CD8-Pacific Blue (53-6.7; BD Biosciences), anti-CXCR3-
APC (CXCR3-173; eBioscience) and anti-CD69-FITC 
(H1.2F3; BD Biosciences). 
Intracellular antigen and cytokine staining
For intracellular cytokine analysis, single cell 
suspensions (0.5-1 million cells per well) were stimulated 
in 24 well plates with complete RPMI containing 20 nM 
phorbol myristate acetate (PMA; Sigma-Aldrich) and 1μg/
ml ionomycin (Sigma-Aldrich), at 37°C for 4 hours. After 
1 hour of incubation, 1μl/ml of GolgiStop (containing 
monensin; BD Biosciences) was added to each well. 
Surface stained cells were stained for intracellular antigen 
following Fixation/Permeabilisation (Foxp3-staining 
kit, eBiosciences). Intracellular antibodies consisted of 
anti-Ki67-FITC (B56; BD Bioscience) or anti-Ki67-
BrilliantViolet 421 (16A8; BioLegend), anti-IL-2-PE 
(JES6-5H4; eBioscience), anti-Foxp3-PE-Cy7 (FJK-16s; 
eBioscience), and anti-T-bet-PerCPCy5.5 (eBio4B10; 
eBioscience). For flow cytometric analysis, samples 
were acquired on a FACS Canto II flow cytometer (BD 
Biosciences), and were subsequently analysed using 
FlowJo software. 
In vitro treg suppression assay 
Single cell suspensions were stained as detailed 
above, using Live/Dead Aqua, anti-CD3-PECy5 (17A2; 
BD Biosciences), anti-CD4-APC-eFluor 780 (RM4-5; 
eBioscience), anti-CD25-PE (PC61; BD Biosciences), 
and anti-CD127-BrilliantViolet605 (A7R34; BioLegend) 
monoclonal antibodies. CD3+ CD4+ CD25lo Tconvs were 
sorted from spleen, and CD3+ CD4+ CD25hi CD127lo 
CD69+ Tregs and CD3+ CD4+ CD25hi CD127lo CD69- 
Tregs were sorted from either non-tumor draining lymph 
nodes or tumor-draining lymph nodes using a customized 
20-parameter FACSAria II flow cytometer (BD). Too few 
Tregs were isolated from pooled tumor samples to perform 
reliable assays. Post-sort purity checks on practice cell 
sorts revealed greater than 98% purity. 
Sorted Tconvs were stained with CellTrace Violet 
(Life Technologies) according to the manufacturers’ 
specifications, pelleted and resuspended in warm complete 
RPMI at a concentration of 2.8 x 105 cells per ml, so as to 
deliver 14, 000 effector cells in 50μl. 
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Sorted Tregs were washed and resuspended 
in warm complete RPMI culture medium (complete 
RPMI supplemented with β-Mercaptoethanol, MEM 
NEAA (100X; gibco) and 5mM HEPES buffer solution 
(gibco)). 14, 000 Tconvs per well were incubated with 
anti-mouse CD3/CD28 dynabeads (Invitrogen) at a ratio 
of 1:2 (beads:Tconvs), with titrating numbers of Tregs, 
in complete RPMI culture medium for 120 hours. After 
72 hours, 100μl of fresh, warm complete RPMI culture 
medium was added. Following culture, cells were stained 
with Live/Dead Aqua, anti-CD3-PE-Cy5, anti-CD4-APC 
eFluor 780 and anti-CD25-PE, as detailed above. Dilution 
of CellTrace Violet was measured on a FACS Canto II 
flow cytometer (BD Biosciences). CD25hi, CellTrace 
Violet negative Tregs were excluded from analysis. 
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